Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Tesla, Inc. (TSLA) Price & Performance

Charles River Laboratories Intl. IncTrade
Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Tesla, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while Tesla, Inc. trades at $326.95 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 97.3× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.

CRLTSLA
Market Cap
$13.46B$1.31T
Sector
HealthConsumer Cyclical
52-Week High
$282.00$489.88
52-Week Low
$145.57$298.16
Enterprise Value
$16.30B$1.29T

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Tesla, Inc.

Tesla (TSLA) trades at $326.95, down 1.18% on the day, amid a bearish technical signal and mixed fundamentals. The stock faces pressure from a recent earnings miss in Q2 2026 but maintains strong operating cash flow of $14.75B in 2025. Recent news highlights regulatory approval for its driver-assistance software in Europe (Reuters, 2026-04-10) and a surge in German registrations, though competition and valuation concerns persist.

Outlook remains bifurcated: long-term growth hinges on AI and autonomy execution, but near-term risks include high P/E of 308.16 and softening auto demand. Analyst consensus price target of $393.87 suggests upside potential if innovation milestones are met, yet investor patience is required amid volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.

Read more on TSLA